article thumbnail

Transforming Biomanufacturing: Potential of Cell Free Systems

Roots Analysis

Biomanufacturing utilizing cell free systems is an emerging area of research that enables the synthesis of different biomolecules, such as cytotoxic proteins, fusion proteins, post translationally modified proteins, antibodies, enzymes, vaccines and other complex proteins, without the use of living cells.

Protein 52
article thumbnail

The latest drug discovery product launches

Drug Discovery World

Gyrolab Biomarker Kits – Gyros Protein Technologies . Gyrolab Human Cytokine Kit Reagents are the first in a range of new biomarker kits from Gyros Protein Technologies. . Scipio bioscience’s single-cell RNA-seq solution includes the Asteria Benchtop Kit and the Cytonaut Cloud Analysis Software. .

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Receptor Occupancy Assays by Flow Cytometry: Benefits for Clinical Trials

XTalks

Flow cytometry is an analytical technique that is used to detect the presence of cell surface markers as well as intracellular proteins using antibodies in individual cells suspended in a buffer solution, which pass through a laser beam one at a time ( Figure 1 ). What is Flow Cytometry? What is a Receptor Occupancy Assay?

article thumbnail

mRNA Synthesis: ManufacturingProcess of Modern Revolutionary Molecule

Roots Analysis

Messenger ribonucleic acid (mRNA) is a single-stranded molecule, which carries coding sequence and plays a prominent role in protein synthesis. It transfers genetic information form to DNA to ribosomes, a specialized structure, or organelle, which decodes genetic information into a protein.

article thumbnail

Reflecting on PEGS Europe 2023 

Drug Discovery World

This presentation covered three primary drivers for a protein expression model: speed, cost and sustainability. “It The next presentation attended in this track was the keynote presentation, which was given by Kate Smith, PhD, Head of UK Protein & Cell Sciences at GSK. GSK has developed high-throughput mammalian and E.

article thumbnail

Casting aside CRISPR scissors and making a point with base editors

pharmaphorum

This can be partly attributed to the reagents and delivery modalities that were available at the time of the trial start in 2016, leading to low editing efficiency at the target loci. However, the number of CAR-T cells with all four genes correctly targeted was low.

article thumbnail

CRISPR breakthroughs: New solutions for common diseases

Drug Discovery World

Current research is focused on designing CRISPR-enhanced CAR T cells that are resistant to immunosuppressive cytokines such as transforming growth factor-β (TGF-β) 2 , programmed cell death protein (PD-1) 3 , or other negative T cell regulators 4 (CTLA-4, LAG-3, and TIM-3), thus improving anti-tumour functions.

DNA 98